Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Edited Transcript of NKTR earnings conference call or presentation 7-May-20 9:00pm GMT
08:12am, Friday, 08'th May 2020
Q1 2020 Nektar Therapeutics Earnings Call
No Surprises in Nektar's Q1; COVID-19 Likely Just a Small Bump in Road for Bempeg Trials
07:57am, Friday, 08'th May 2020Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2020 Results - Earnings Call Transcript
07:31am, Friday, 08'th May 2020
Nektar Therapeutics (NASDAQ:NKTR) Q1 2020 Earnings Conference Call May 7, 2020 17:00 ET Company Participants Jennifer Ruddock - SVP, Strategy & Corporate Af
Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript
07:31am, Friday, 08'th May 2020
NKTR earnings call for the period ending March 31, 2020.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Thursday, 07'th May 2020
Nektar (NKTR) delivered earnings and revenue surprises of 34.57% and 12.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics Q1 EPS $(0.530) Beats $(0.710) Estimate, Sales $50.573M Beat $47.640M Estimate
09:13pm, Thursday, 07'th May 2020Nektar Therapeutics Reports First Quarter 2020 Financial Results
08:15pm, Thursday, 07'th May 2020
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020.
Pear Therapeutics to Present at the Bank of America Merrill Lynch 2020 Virtual Healthcare Conference
12:00am, Thursday, 07'th May 2020
Pear Therapeutics to Present at the Bank of America Merrill Lynch 2020 Virtual Healthcare Conference
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Xeris Pharmaceuticals (XERS) Gets a Buy Rating from Mizuho Securities
12:56pm, Friday, 01'st May 2020
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The
Xeris Pharmaceuticals (XERS) Gets a Buy Rating from Mizuho Securities
12:56pm, Friday, 01'st May 2020
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
04:33pm, Thursday, 30'th Apr 2020
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
04:33pm, Thursday, 30'th Apr 2020
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mizuho Securities Maintains a Buy Rating on Sarepta Therapeutics (SRPT)
08:11am, Thursday, 30'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Sarepta Therapeutics (SRPT) today and set a price target of $183.00. The company's shares
